Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom.
Pharmacoeconomics
; 18(2): 143-8, 2000 Aug.
Article
em En
| MEDLINE
| ID: mdl-11067648
ABSTRACT
OBJECTIVE:
To estimate the cost effectiveness of different classes of antidepressants in the UK National Health Service. DESIGN, PATIENTS ANDINTERVENTIONS:
The use of the serotonin (5-hydroxytryptamine; 5-HT) and noradrenaline (norepinephrine) reuptake inhibitor (SNRI) venlafaxine was compared with that of selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) in patients with major depressive disorder (MDD). A meta-analysis determined the clinical success rate, and a decision tree was constructed by interviewing general practitioners and psychiatrists. Adding pharmacological and nonpharmacological treatment costs, meta-analytic rates were applied to the decision tree to calculate the expected cost and outcome for each drug. Cost effectiveness was determined using a composite measure of outcome [symptom-free days (SFD)]. MAIN OUTCOME MEASURES ANDRESULTS:
The meta-analysis included data from 44 studies on 4033 patients. The highest overall efficacy rate for outpatients with MDD was with venlafaxine use (73.7%), compared with 61.4% for SSRIs and 59.3% for TCAs. Treatment with venlafaxine yielded the lowest outpatient cost for a SFD (10.53 Pounds), compared with 13.23 Pounds for SSRIs and 15.52 Pounds for TCAs (1998 values).CONCLUSIONS:
Using this economic model, venlafaxine appears to be a cost-effective treatment for outpatients with MDD in the UK.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Transtorno Depressivo
/
Antidepressivos
Tipo de estudo:
Health_economic_evaluation
/
Prognostic_studies
/
Systematic_reviews
Limite:
Humans
Idioma:
En
Revista:
Pharmacoeconomics
Assunto da revista:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Ano de publicação:
2000
Tipo de documento:
Article
País de afiliação:
Reino Unido
País de publicação:
NEW ZEALAND
/
NOVA ZELÂNDIA
/
NUEVA ZELANDA
/
NZ